secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2026-05-14T11:06:42+00:00
Accession:  0001759138-26-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q1: R&D $37.4M, cash $116.6M; $150M equity raise; rese-cel advances
--------------------------------------------------------------------------------

- R&D expenses $37.4M (up 29% YoY); G&A $6.9M (down 15% YoY); cash $116.6M as of March 31, 2026.
- Post-quarter $150M registered direct offering closed in May 2026, extends cash runway into mid-2027.
- Preconditioning-free rese-cel data presented at ASGCT; lowest dose showed drug-free responses in 4 PV patients.
- Registrational RESET-Myositis trial progressing with BLA submission planned for 2027; higher dose and longer-term data expected 2H26.
- Entered 10-year commercial supply agreement with Cellares for automated manufacturing of rese-cel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/0001759138-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000025/caba-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001759138-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer